arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Armata Pharmaceuticals, Inc.

ARMP

$4.66 ▼ -0.01 (-0.21%) at close

14 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Good

Bullish

auto_awesome

Analytical Summary

Armata Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $168.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 13.2% ↘

FCF / Share $-0.73 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-173.80M

↓ -818.8% —

FCF / Share Free cash flow per share

$-0.73

↑ +33.4% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
EPS Growth YoY (%)	-823.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	72.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-76.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-12.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	28.9% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	45.8% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	30.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	87.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	91.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-12297.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—	—
Net Income Growth YoY (%)	-818.8% Weak ↓ Weak Declining Year-over-year change in net income	72.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-87.0% Weak ↓ Weak Declining Year-over-year change in net income	-59.4% Weak ↓ Weak Declining Year-over-year change in net income	-4.4% Weak ↑ Weak Improving Year-over-year change in net income	-13.9% Weak ↓ Weak Declining Year-over-year change in net income	-16.6% Weak ↑ Weak Improving Year-over-year change in net income	-30.1% Weak ↑ Weak Improving Year-over-year change in net income	31.9% Excellent Excellent Year-over-year change in net income	-3550.8% Weak Weak Year-over-year change in net income	N/M	N/M	—	—
FCF Growth YoY (%)	33.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	29.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-52.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	2.0% Caution ↓ Caution Declining Year-over-year change in free cash flow	11.3% Fair ↓ Fair Declining Year-over-year change in free cash flow	42.4% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	18.3% Good ↓ Good Declining Year-over-year change in free cash flow	87.8% Excellent Excellent Year-over-year change in free cash flow	86.9% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
FCF / Net Income (x)	0.15x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	2.08x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.58x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Return on Invested Capital (%)	13.2% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	69.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	100.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-80.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-74.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-90.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-106.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-181.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-165.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-189.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-63.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-324.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	43.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-47.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-38.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-54.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-77.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-121.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-145.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-128.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-49.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-30.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	79.5% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+430%)	39.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+163%)	215.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1336%)	-102.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-782%)	-91.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-708%)	-117.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-884%)	-133.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-990%)	-217.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1547%)	-166.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1207%)	-193.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1392%)	-4.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-127%)	—	285.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1803%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Interest Coverage (x)	—	—	—	—	-372.22x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-34.37x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-21.22x Weak Weak Operating income divided by interest expense Optimal: > 5x	-17.43x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	-53.15x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-8.69M	$-9.29M	$-13.52M	$-14.85M	$-10.29M	$-9.65M	$-6.03M	$-9.66M	$-5.13M	$-5.71M	$-9.37M	$-6.58M	$-20.36M	$-862.00K

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Basic EPS, GAAP (USD)	$-4.80	$-0.52	$-1.91	$-1.08	$-0.96	$-1.35	$-2.49	$-3.59	$-28.15	$-345.52	$-2.79	$0.00	$-0.02	—
Free Cash Flow per Share (USD)	$-0.73	$-1.09	$-1.54	$-1.01	$-1.03	$-1.16	$-2.02	$-2.47	$-20.28	$-154.95	—	—	—	—
Book Value per Share (USD)	$-6.00	$-1.33	$-0.89	$1.00	$0.94	$1.01	$1.47	$1.52	$11.40	$82.59	$3.03	$0.00	$-0.00	—
Tangible Book Value per Share (USD)	$-6.38	$-1.71	$-1.27	$0.62	$0.43	$0.27	$0.09	$1.52	$4.53	$-6.27	$-1.74	$-0.00	$-0.01	—
Basic Weighted Avg Shares (shares)	36.24M	36.16M	36.08M	34.29M	24.10M	16.42M	7.83M	4.65M	456,062	70,247	3.86M	6.69B	3.61B	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Working Capital (USD)	$1.72M	$-36.94M	$2.69M	$2.17M	$10.18M	$4.14M	$1.78M	$8.33M	$3.42M	$2.77M	$7.63M	$5.15M	$18.27M	—
Total Equity (USD)	$-218.60M	$-48.02M	$-32.06M	$36.08M	$25.40M	$18.86M	$14.59M	$7.69M	$7.73M	$9.72M	$12.71M	$3.44M	$-22.62M	$12.94M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Depreciation Expense (USD)	$1.53M	$1.32M	$972.00K	$892.00K	$1.17M	$1.11M	$1.35M	$1.35M	$343.00K	$338.00K	$299.00K	$127.00K	$82.00K	—
Net Income, GAAP (USD)	$-173.80M	$-18.92M	$-69.05M	$-36.92M	$-23.16M	$-22.18M	$-19.48M	$-16.70M	$-12.84M	$-18.84M	$-516.00K	$23.11M	$-64.58M	—
Operating Cash Flow (USD)	$-25.76M	$-37.55M	$-47.42M	$-32.48M	$-23.57M	$-18.27M	$-15.58M	$-10.63M	$-9.19M	$-10.61M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 54 quarters

Armata Pharmaceuticals, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ARMP with peers